U.S. Electrical Stock News

NasdaqGS:GFS
NasdaqGS:GFSSemiconductor

GLOBALFOUNDRIES (GFS) Secures $300 Million CHIPS Backing, Is The Pullback A Buying Opportunity?

GLOBALFOUNDRIES (GFS) moved into the spotlight after signing a letter of intent with the U.S. Department of Commerce for a planned US$300 million CHIPS Act R&D award focused on silicon photonics for AI infrastructure. See our latest analysis for GLOBALFOUNDRIES. GLOBALFOUNDRIES shares have been volatile, with a 30-day share price return down 35.27% and a 90-day share price return down 22.99%. However, the year to date share price return is up 35.58% and the 1-year total shareholder return is...
NasdaqGS:EYE
NasdaqGS:EYESpecialty Retail

Is National Vision Holdings (EYE) Undervalued Or Is Its Rich P E Already Priced In?

How National Vision Holdings Stock Has Been Trading National Vision Holdings (EYE) has drawn attention after a recent share price move, with the stock closing at US$22.04 on 29 July 2026. Investors are weighing this against mixed recent total return figures. See our latest analysis for National Vision Holdings. For context, National Vision Holdings has recently seen a 7 day share price return of 10.64% and a 30 day share price return of 16.00%, while the year to date share price return is...
NasdaqGM:GHRS
NasdaqGM:GHRSPharmaceuticals

Is GH Research (GHRS) Fully Valued Following Its Share Price Surge?

GH Research (NasdaqGM:GHRS) has drawn attention after recent share price moves, with the stock last closing at $28.07. Investors are weighing clinical progress in depression treatments against ongoing losses and early stage revenue. See our latest analysis for GH Research. For context, GH Research has shown strong momentum over longer periods, with a 35.54% 90 day share price return and a 104.29% 1 year total shareholder return that reflects shifting expectations around its depression...
NasdaqGS:CCNE
NasdaqGS:CCNEBanks

Is CNB Financial (CCNE) Undervalued After Its Q2 2026 Results?

CNB Financial (CCNE) is back on investor watch after reporting second quarter 2026 results on 23 July, followed by a KBW Summer Bank Conference appearance that keeps attention on its earnings profile and loan performance. See our latest analysis for CNB Financial. Since those July updates, CNB Financial’s share price has climbed to $35.10, with a 90 day share price return of 14.41% and a year to date share price return of 36.36%. The 1 year total shareholder return of 60.31% points to...
NYSE:OPY
NYSE:OPYCapital Markets

Should Oppenheimer’s Strong Q2 Results and Dividend Declaration Prompt Action From Oppenheimer Holdings (OPY) Investors?

Oppenheimer Holdings Inc. has reported second-quarter 2026 results, with revenue rising to US$454.88 million and net income reaching US$27.35 million, while its Board declared a US$0.20 per-share quarterly dividend payable on August 28, 2026. Despite much stronger second-quarter profit than a year earlier, net income for the first half of 2026 was only US$6.77 million, highlighting how earlier-period pressures contrast with the recent quarter’s momentum in Wealth Management and Capital...
NYSE:GPK
NYSE:GPKPackaging

Graphic Packaging Holding (GPK) Stock Could Trade At A Discount On A 50% Three Year Slump

Graphic Packaging Holding stock has had a difficult run over the past few years, yet the current valuation checks suggest the market may now be pricing it on the cheap side. For investors, the gap between the share price performance and the valuation metrics is what stands out. Over the past 3 years, Graphic Packaging Holding shareholders have seen the stock decline about 50.5%, which signals a heavy reset in market expectations. The key support for the valuation is whether the company can...
NYSE:WES
NYSE:WESOil and Gas

Is Western Midstream Partners (WES) Fairly Valued Following Its Dividend Announcement And Upcoming Earnings?

Western Midstream Partners (WES) is back in focus after a $0.93 cash dividend announcement coincided with an upcoming earnings release and a fresh shelf registration for 19,389,239 common units worth about $929.3m. See our latest analysis for Western Midstream Partners. Western Midstream Partners’ recent 1 day share price decline of 2.0% and 7 day share price decline of 1.9% sit against a stronger backdrop, with a 30 day share price return of 8.0% and a 1 year total shareholder return of...
NasdaqGS:OKTA
NasdaqGS:OKTAIT

Okta (OKTA) Stock Looks Expensive With Fair Value Largely Priced In

After a strong three year run for Okta, where the stock has returned 95.6%, the current valuation picture looks far from a clear bargain as traditional checks flag the shares as expensive even though a Discounted Cash Flow (DCF) intrinsic value estimate points to pricing that is roughly in line with fundamentals. Over the past 3 years, Okta has delivered a 95.6% return, which puts extra focus on whether today’s price still offers enough compensation for risk. Expectations for Okta to keep...
NYSE:PK
NYSE:PKHotel and Resort REITs

Park Hotels & Resorts (PK) Gains On Strong Momentum, Is The Stock Still Below Fair Value?

Management update at Park Hotels & Resorts stock Park Hotels & Resorts (PK) is in focus after Jisun Song was appointed Director of Operations at Park Hyatt St. Kitts Christophe Harbour, which highlights how management decisions at key properties can matter for investors. See our latest analysis for Park Hotels & Resorts. Beyond this management change, Park Hotels & Resorts' recent share price return has been strong, with a 30 day share price return of 6.28% and a 90 day share price return of...
NasdaqGS:DYN
NasdaqGS:DYNBiotechs

Dyne Therapeutics (DYN) Could Be 38% Undervalued As FDA Milestones Lift Pipeline Hopes

Dyne Therapeutics (DYN) has been in focus after back to back U.S. FDA milestones, including clearance to begin a Phase 1 trial for DYNE-302 and Priority Review for Duchenne candidate DYNE-251. See our latest analysis for Dyne Therapeutics. Recent regulatory milestones appear to be feeding into Dyne Therapeutics' share price momentum, with the stock at US$25.18 after a 15.56% 30 day share price return and a 150.55% 1 year total shareholder return, even as recent losses and the July follow on...
NYSE:STVN
NYSE:STVNLife Sciences

Stevanato Group (STVN) Could Be 19% Undervalued As Alina Pen Approvals Expand In Europe

Stevanato Group (STVN) stock is in focus after the company reported that liraglutide combination products using its Alina 30 and Alina 50 pen injectors received marketing authorizations in multiple European countries. See our latest analysis for Stevanato Group. The Alina approvals come as Stevanato Group’s share price shows mixed momentum, with a 30 day share price return of 8.23% and a 90 day share price return of 12.08%. However, the year to date share price return is down 3.55% and the 1...
NYSE:MIR
NYSE:MIRElectronic

Why Mirion Technologies (MIR) Is Down 9.4% After Reaffirming 2026 Growth Guidance And Robust Backlog

In late July 2026, Mirion Technologies reported second-quarter 2026 results showing revenue of US$266.8 million versus US$222.9 million a year earlier, with net income easing to US$7.7 million from US$8.3 million, and reaffirmed full-year 2026 guidance for revenue growth of about 22%–24% including foreign exchange and acquisition-related benefits. Beneath modest earnings per-share movement, Mirion highlighted strong order growth, a backlog above US$1.10 billion, and growing nuclear-sector...
NYSE:RITM
NYSE:RITMMortgage REITs

Is Rithm Capital (RITM) Undervalued As Strong Quarterly Earnings Lift Its Outlook?

What Rithm Capital’s Latest Quarter Tells Investors Rithm Capital (RITM) is back in focus after reporting second quarter 2026 results, with sales of US$236.69 million and net income of US$56.29 million. These figures underline stronger earnings available for distribution. See our latest analysis for Rithm Capital. Rithm Capital’s 1 day share price return of 0.10% and 7 day share price return of 8.33% sit against a year to date share price decline of 10.02% and a 5 year total shareholder...
NasdaqGS:PENG
NasdaqGS:PENGSemiconductor

Will Record Q3 AI-Driven Sales Surge and Higher Guidance Change Penguin Solutions' (PENG) Narrative?

Penguin Solutions, formerly SMART Global Holdings, recently reported record Q3 fiscal 2026 net sales of about US$479 million, a very large year-over-year increase that prompted management to lift full-year revenue growth guidance to approximately 22%. An interesting angle is that AI-related businesses now contribute 74% of Penguin’s total sales and grew at a very large rate over the past year, underscoring how quickly the company’s revenue mix is tilting toward AI infrastructure...
NasdaqGS:TARS
NasdaqGS:TARSPharmaceuticals

The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following Sharp EPS Estimate Cuts Amid Rising Sales

Tarsus Pharmaceuticals recently faced significantly lowered consensus earnings-per-share estimates and a low analyst ranking ahead of its June 2026 quarterly results, even as revenue was projected to increase year over year. This combination of weaker profit expectations and growing sales highlights a tension between top-line momentum and concerns about the company’s near-term earnings profile. Now we’ll examine how this sharp downward revision in earnings expectations may affect Tarsus...
NasdaqGS:NXT
NasdaqGS:NXTElectrical

Nextpower (NXT) Expands Clean Energy Platform As Record Q1 Revenue And Backlog Land

Nextpower (NasdaqGS:NXT) reported record Q1 FY2027 revenue and backlog, highlighting strong execution in its core clean energy business. The company moved to expand its power conversion capabilities through the acquisition of assets from Zigor Corporation and Apex Power. Nextpower agreed to acquire Prevalon energy storage and Zimmermann PV-Steel Group to extend its platform in large scale solar and storage. Nextpower enters this news cycle with its stock at $89.87, after a gain of 58.9%...
NYSE:PFS
NYSE:PFSBanks

Provident Financial Services (PFS) Earnings Strength Keeps Valuation In Focus

Provident Financial Services (PFS) is back in focus after reporting record quarterly revenue and a 17% year over year increase in earnings per share, supported by strong commercial loan production and a sizable loan pipeline. See our latest analysis for Provident Financial Services. Provident Financial Services shares recently eased 0.72% on the day to $24.68, while the 90 day share price return of 10.28% and 1 year total shareholder return of 43.53% indicate momentum that has been building...
NYSE:YELP
NYSE:YELPInteractive Media and Services

Is Yelp’s (YELP) AI Restaurant Push Quietly Rewriting Its Core Competitive Moat?

In July 2026, Yelp Inc. reported that its AI-powered Yelp Host for restaurants has now handled over 1 million calls since launching in October 2025, added OpenTable integration across the US and Canada, and expanded into takeout ordering via direct POS connections with systems like Toast, Square, and Clover. This marks Yelp’s push beyond reservations into end-to-end, AI-driven restaurant operations, potentially deepening its role in automating front-of-house and takeout workflows for both...
NYSE:CNC
NYSE:CNCHealthcare

How Centene’s Upgraded 2026 Outlook and Capital Moves Could Shape CNC Investors’ Risk‑Reward Profile

In late July 2026, Centene reported second-quarter revenue of US$53,579 million and net income of US$1,091 million, raised its 2026 revenue and GAAP EPS guidance, announced a US$500,000,000 partial redemption of its 4.25% 2027 Notes, completed a long-running buyback program, and made changes to its board. The combination of stronger profitability, updated full-year outlook, balance sheet actions, and refreshed board composition offers a clearer view of how Centene is positioning its capital...
NYSE:SRE
NYSE:SREIntegrated Utilities

Sempra (SRE) Stock Looks Above Fair Value Despite Fair Earnings Pricing

Sempra stock has delivered a 56.5% total return over the past five years, yet its current checks suggest the shares do not stand out as a clear bargain today. Recent headlines around wildfire liability debates and major LNG project timing give investors fresh reasons to reassess what they are paying for the company’s future cash flows. A 56.5% gain over five years highlights that Sempra has already rewarded long term holders, which can limit how much potential upside remains if expectations...
NasdaqGS:NVMI
NasdaqGS:NVMISemiconductor

Nova (NVMI) Could Be 35% Undervalued As AI Chip Demand Draws Fresh Attention

Nova (NasdaqGS:NVMI) drew fresh attention after reports of broader global adoption of its metrology tools in advanced packaging and AI driven chip production at major foundries, with investors also watching for upcoming quarterly earnings. See our latest analysis for Nova. Over the past month the stock has come under pressure, with a 30 day share price return down 22.23% and a 90 day share price return down 20.95%. However, Nova still shows stronger longer term momentum with a 1 year total...
NasdaqGS:ZION
NasdaqGS:ZIONBanks

Zions Bancorporation (ZION) Lifts Dividend 6.7% And Adds $75 Million Buyback

Zions Bancorporation National Association (NasdaqGS:ZION) announced a 6.7% increase in its quarterly common dividend. The company also authorized a new US$75 million share repurchase program scheduled for the third quarter of 2026. Zions Bancorporation National Association focuses on regional banking services, including lending, deposit gathering, and treasury offerings for businesses and consumers. Dividend decisions and buyback authorizations are closely watched in the banking sector,...
NYSE:RCUS
NYSE:RCUSBiotechs

How Investors May Respond To Arcus Biosciences (RCUS) Expanding ARC-20 With New Kidney Cancer Combo

Arcus Biosciences and Summit Therapeutics previously announced a clinical trial collaboration to test Arcus’s oral HIF-2a inhibitor casdatifan with Summit’s PD-1/VEGF bispecific antibody ivonescimab in metastatic clear cell renal cell carcinoma, adding a new combination cohort to Arcus’s ongoing ARC-20 platform study. An interesting aspect of this collaboration is that both companies retain full rights to their own drugs while sharing study costs, potentially expanding each firm’s kidney...
NYSE:CRCL
NYSE:CRCLSoftware

Circle Internet Group (CRCL) Faces A New Valuation Test Following New York Trust Approval

Circle Internet Group (CRCL) has secured a limited purpose trust charter from the New York Department of Financial Services for Circle New York Trust, a development that sharpens the regulatory profile around USDC oversight and custody operations. See our latest analysis for Circle Internet Group. Despite the New York trust charter and earlier approval to establish a national trust bank, Circle Internet Group’s 1-year total shareholder return declined 62.75%, with the share price at $62.61...